Atherosclerosis in autoimmune diseases

Current Rheumatology Reports

Volumn 11, Issue 1, 2009, Pages 61-69

  Matsuura, Eiji ^a   Kobayashi, Kazuko ^a   Lopez, Luis R ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COPPER ION; FC RECEPTOR; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; AUTOANTIBODY; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CELL MIGRATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; LIPID PEROXIDATION; MACROPHAGE FUNCTION; OXIDATIVE STRESS; PROTEIN MODIFICATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM; AUTOIMMUNITY; BLOOD; IMMUNOLOGY; METABOLISM;

ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; HUMANS; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; OXIDATIVE STRESS;

EID: 63449121972     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0009-1     Document Type: Review

References (64)

1. Aranow C, Ginzler EM: Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000, 9:166-169.
2. Steinberg D: Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
3. Heinecke JW: Mechanisms of oxidative damage of lowdensity lipoprotein in human atherosclerosis. Curr Opin Lipid 1997, 8:268-274.
4. Hughes GR, Harris EN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol 1986, 13:486-489.
5. Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
6. Vaarala O: Antiphospholipid antibodies in myocardial infarction. Lupus 1998, 7:S132-S134.
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
8. Matsuura E, Igarashi Y, Yasuda T, et al.: Anticardiolipin antibodies recognize b2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994, 179:457-462.
9. Brey RL, Abbott RD, Curb JD, et al.: Beta2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction. Stroke 2001, 32:1701-1706.
10. Lopez LR, Dier KJ, Lopez D, et al.: Anti-b2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004, 121:142-149.
11. George J, Harats D, Gilburd B, et al.: Immunolocalization of b2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227-2230.
12. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al.: Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989, 85:1086-1095.
13. Kobayashi K, Kishi M, Atsumi T, et al.: Circulating oxidized LDL forms complexes with b2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 2003, 44:716-726.
14. Hasunuma Y, Matsuura E, Makita Z, et al.: Involvement of b2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573.
15. Kobayashi K, Matsuura E, Liu Q, et al.: A specific ligand for b2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
16. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR: Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006, 45: 466-486.
17. Lopez D, Kobayashi K, Merrill JT, et al.: IgG Autoantibodies against b2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 2003, 10: 203-211.
18. American Heart Association: Heart Disease and Stroke Statistics - 2005 Update. Available at http://www.americanheart.org. Accessed on September 25, 2008.
19. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
20. Virella G, Atchley DH, Koskinen S, et al.: Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002, 105:81-92.
21. Salonen JT, Yla-Herttuala S, Yamamoto R, et al.: Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
22. Esdaile JM, Abrahamowicz M, Grodzicky T, et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
23. Thomas RH: Hypercoagulability syndromes. Arch Intern Med 2001, 161:2433-2439.
24. Wahl DG, Guillemin F, de Maistre E, et al.: Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta analysis. Lupus 1997, 6:467-473.
25. Shah NM, Khamashta MA, Atsumi T, Hughes GR: Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients. Lupus 1998, 7:3-6.
26. Cervera R, Piette JC, Font J, et al.: Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
27. George J, Harats D, Gilburd B, et al.: Adoptive transfer of b2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000, 102:1822-1827.
28. Cushing SD, Berliner JA, Valente AJ, et al.: Minimally modified low-density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990, 87:5134-5138.
29. Frostegard J, Wu R, Haegerstrand A, et al.: Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 1993, 103:213-219.
30. Mach F, Schonbeck U, Sukhova GK, et al.: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394: 200-203.
31. Fong LG, Parthasarathy S, Witztum JL, Steinberg D: Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 1987, 28:1466-1467.
32. Kleinveld HA, Hak-Lemmers HL, Stalenhoef AF, Demacker PN: Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992, 38:2066-2072.
33. Parthasarathy S, Fong LG, Quinn MT, Steinberg D: Oxidative modification of LDL: Comparison between cell-mediated and copper-mediated modification. Eur Heart J 11(Suppl E):83-87.
34. Podrez EA, Abu-Soud HM, Hazen SL: Myeloperoxidase-generated oxidants and atherosclerosis. Free Rad Biol Med 1999, 28: 1717-1725.
35. Yamamoto T, Davis AG, Brown MS, et al.: The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984, 39: 27-38.
36. Brown MS, Goldstein JL: Scavenger cell receptor shared. Nature 1985, 316:680-681.
37. Kodama T, Reddy P, Kishimoto C, Krieger M: Purification and characterization of a bovine acetyl low-density lipoprotein receptor. Proc Natl Acad Sci U S A 1988, 85:9238-9242.
38. Ramprasad MP, Fischer W, Witztum JL, et al.: The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A 1995, 92:9580-9584.
39. Sawamura T, Kume N, Aoyama T, et al.: An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386:73-77.
40. Shimaoka T, Kume N, Minami M, et al.: Molecular cloning of a novel scavenger receptor for oxidized low-density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000, 275:40663-40666.
41. Hoshino M, Hagihara Y, Nishii I, et al.: Identification of the phospholipid-binding site of human b2-glycoprotein I domain V by heteronuclear magnetic resonance. J Mol Biol 2000, 304:927-939.
42. Inanc M, Radway-Bright EL, Isenberg DA: Beta2-glycoprotein I and anti-b2-glycoprotein I antibodies: Where are we now? Br J Rheumatol 1997, 36:1247-1257.
43. Merrill JT, Zhang HW, Shen C, et al.: Enhancement of Protein S anticoagulant function by b2-glycoprotein I, a major target antigen of antiphospholipid antibodies: B2-glycoprotein I interferes with binding of Protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999, 81:748-757.
44. Morgan PE, Sturgess AD, Davies M: Increased levels of serum protein oxidation and correlation with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:2069-2079.
45. Frostegard J, Svenungsson E, Wu R, et al.: Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005, 52:192-200.
46. Lopez D, Garcia-Valladares I, Palafox-Sanchez C, et al.: Oxidized low-density lipoprotein/b2-glycoprotein I complexes and autoantibodies to oxLig-1/b2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 2004, 121:426-436.
47. Lopez LR, Simpson DF, Hurley BL, Matsuura E: OxLDL/b2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome. Pathogenic implications for vascular involvement. Ann NY Acad Sci 2005, 1051:313-322.
48. Matsuura E, Kobayashi K, Inoue K, et al.: Oxidized LDL/b2-glycoprotein I complexes: New aspects in atherosclerosis. Lupus 2005, 14:736-741.
49. Ayada K, Yokota K, Kobayashi K, et al.: Chronic infections and atherosclerosis. Ann NY Acad Sci 2007, 1108:594-602.
50. Liu Q, Kobayashi K, Furukawa J, et al.: Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 2002, 43:1486-1495.
51. Tabuchi M, Inoue K, Usui-Kataoka H, et al.: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007, 48:768-781.
52. Kobayashi K, Lopez LR, Matsuura E: Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Ann N Y Acad Sci 2007, 1108:489-496.
53. Kobayashi K, Tada K, Itabe H, et al.: Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 2007, 16:929-938.
54. Kuwana M, Matsuura E, Kobayashi K, et al.: Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557.
55. Yamaguchi Y, Seta N, Kaburaki J, et al.: Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007, 110:4312-4318.
56. Kajiwara T, Yasuda T, Matsuura E: Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 2007, 29:164-173.
57. Kasahara J, Kobayashi K, Maeshima Y, et al.: Clinical significance of serum oxidized low-density lipoprotein/β2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 2004, 98:c15-24.
58. Ames PR, Margarita A, Sokoll KB, et al.: Premature atherosclerosis in primary antiphospholipid syndrome: Preliminary data. Ann Rheum Dis 2005, 64:315-317.
59. Matsuura E, Kobayashi K, Tabuchi M, et al.: Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006, 32:537-551.
60. Margarita A, Batuca J, Scenna G, et al.: Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 2007, 1108:475-480.
61. Matsuura E, Kobayashi K, Lopez LR: Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 2008, 7:214-222.
62. Ames PR, Margarita A, Alves JD: Antiphospholipid antibodies and atherosclerosis: Insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2008 [Epub ahead of print].
63. Matsuura E, Lopez LR: Autoimmune-mediated atherothrombosis. Lupus 2008, 17:878-887.
64. Ames PR, Antinolfi I, Ciampa A, et al.: Primary antiphospholipid syndrome: A low-grade auto-inflammatory disease? Rheumatology 2008, 47:1832-1837.